活性成分
产量(工程)
过程开发
水解
酰胺
组合化学
化学
杂质
钠
工艺工程
有机化学
材料科学
工程类
生物
冶金
生物信息学
作者
Anna M. Wagner,Sara A. Bonderoff,Shoou‐Yuh Chang,Jeffrey Deignan,Michelle M. Esanu,H Huynh,Tyan-Min Niu,V. Thanh Ngo,B. Michael O’Keefe,Jenny Phoenix,Trevor J. Rainey,Benjamin Roberts,Jinyu Shen,Craig R. Stewart,Amanda L. Vandehey,Scott A. Wolckenhauer,C. Y. Wong,Brian H. Yarmuch
标识
DOI:10.1021/acs.oprd.4c00242
摘要
Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.
科研通智能强力驱动
Strongly Powered by AbleSci AI